Business
mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar development
mAbxience, a Fresenius entity, and HP Inc., a global leader in technology, announce a new project to develop an innovative artificial intelligence (AI) solution that optimizes the production process of monoclonal antibodies and biosimilars.
About this update from Hp Inc.
[{"type":"text","content":"MADRID, Dec. 4, 2025 /PRNewswire/ -- mAbxience, a Fresenius entity, and HP Inc., a global leader in technology, announce a new project to develop an innovative artificial intelligence (AI) solution that optimizes the production process of monoclonal antibodies and biosimilars.","length":282,"tagName":"p"},{"type":"image","alt":"Mabxience company facilities","displaySize":"","headline":null,"caption":"Mabxience company facilities","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/60bb6d6aaf94dc7a3cc28664d267d415"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eO4tKFnweiU5SI4SZbB.yA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/60bb6d6aaf94dc7a3cc28664d267d415","width":400,"height":267}}},{"type":"text","content":"The project represents a pioneering step in the application of AI to industrial biotechnology through the creation of a digital twin of the biological process, designed to enhance predictability, consistency, and efficiency in large-scale production."This is a clear example of technology with purpose: we use artificial intelligence not only to optimize processes but to help critical treatments reach more people, faster and better," said Sergio Martínez, Technical Lead of the project at HP.","length":504,"tagName":"p"},{"type":"text","content":"Beyond its technological innovation, this solution holds transformational potential for all of mAbxience's partners, both biosimilar licensees and CDMO clients. By integrating AI into its manufacturing operations, mAbxience aims to significantly optimize its development approach towards biologics development, enhancing operational efficiencies, and optimizing resource utilization. This advancement will strengthen the company's position as a trusted, cost-competitive global biomanufacturing partner, while helping to optimize patient access to safe, high-quality biologic medicines.","length":594,"tagName":"p"},{"type":"text","content":""Artificial intelligence may open a lot of yet untapped potential for biomanufacturing optimization," said Timo Liebig, Chief Innovation Officer at mAbxience.","length":168,"tagName":"p"},{"type":"text","content":""Through this collaboration with HP, we have successfully develo...